Workflow
迈瑞医疗(300760):单三季度迎来拐点,国际市场表现亮眼

Investment Rating - The investment rating for the company has been downgraded to "Outperform" [1][4][10] Core Insights - The company achieved a revenue of 25.83 billion RMB in the first three quarters of 2025, reflecting a decrease of 12.38% year-on-year, with a net profit attributable to shareholders of 7.57 billion RMB, down 28.83% [4][10] - The third quarter revenue was 9.09 billion RMB, marking a growth of 1.53%, indicating a turning point for the company [4][10] - Preliminary estimates suggest that the revenue growth for Q4 2025 will accelerate compared to Q3 2025 [4][10] - The international market performance has been strong, with international business growing by 12% year-on-year in Q3, particularly in Europe, which saw growth exceeding 20% [4][10] Financial Summary - Total revenue projections for the upcoming years are as follows: - 2023: 34,932 million RMB - 2024: 36,726 million RMB - 2025: 33,587 million RMB (down 8.5%) - 2026: 38,724 million RMB (up 15.3%) - 2027: 44,095 million RMB (up 13.9%) [3][5] - Net profit attributable to shareholders is projected as follows: - 2023: 11,582 million RMB - 2024: 11,668 million RMB - 2025: 9,744 million RMB (down 16.5%) - 2026: 11,444 million RMB (up 17.4%) - 2027: 13,226 million RMB (up 15.6%) [3][5] - The company is assigned a PE ratio of 28X for 2025, with a target price of 225.12 RMB [4][10] International Market Performance - The company has made significant progress in international markets, with a balanced revenue distribution globally [4][10] - The growth in international business is attributed to breakthroughs with high-end overseas clients and improved local platform capabilities [4][10] - The company plans to enhance its global supply chain and local production to support sustained international growth [4][10]